Twitter | Search | |
CancerProgress by Cello Health BioConsulting
Cello Health BioConsulting (Previously Defined Health), the leading science-based Oncology consultancy. Visit Cancer Progress 2018, May 7-8, NYC.
2,101
Tweets
1,497
Following
513
Followers
Tweets
CancerProgress by Cello Health BioConsulting May 11
Great article by the fantastic Dr. Peter Bach. Nice acknowledgment in figures and at bottom of article. || Biologics Are Natural Monopolies (Part 1): Why Biosimilars Do Not Create Effective Competition | Health Affairs
Reply Retweet Like
CancerProgress by Cello Health BioConsulting May 10
A truly fantastic panel! Jeff Bockman moderates Combination Failures & Futures: Much Ado About What? with panelists Kapil Dhingra, Axel Hoos, Ramy Ibrahim, Vanessa M. Lucey, PhD, MBA, Robert Stein, and Mai-Britt Zocca
Reply Retweet Like
CancerProgress by Cello Health BioConsulting May 9
Great session, thanks for the data, Jun, and to CRI for having Jill and Vanessa on panels. mmunotherapy
Reply Retweet Like
CancerProgress by Cello Health BioConsulting retweeted
Cancer Research Institute Apr 19
Our Clinical Accelerator team updated their timeline of anti-PD-1/L1 antibody approvals by the FDA for the recent approval of pembrolizumab as the first-line use in patients with stage 3 non-small cell lung cancer ():
Reply Retweet Like
CancerProgress by Cello Health BioConsulting Apr 19
A startup's goal: Kill cancer with pills targeting RNA, not proteins - STAT
Reply Retweet Like
CancerProgress by Cello Health BioConsulting Apr 17
BIO Convention on Twitter: "Curious about what's next in the field of immuno-oncology? You won't want to miss this session, led by experts from , & . " / Twitter
Reply Retweet Like
CancerProgress by Cello Health BioConsulting retweeted
Brad Loncar Apr 12
This was the vaccine NewLink Genetics owned (and since licensed to Merck). Many people laughed at the time, but at least they have this positive legacy of saving some lives.
Reply Retweet Like
CancerProgress by Cello Health BioConsulting retweeted
Anirban Maitra Apr 12
The cancer biomarker field is a mess, from overfitting of data to use of cases v controls that are not appropriate for intended clinical use. It is imperative that journal editors use reviewers with a cancer biostatistics background for evaluating papers.
Reply Retweet Like
CancerProgress by Cello Health BioConsulting retweeted
CancerProgress by Cello Health BioConsulting Apr 3
Late-breaking additions to our CP panels, making them all the more stellar! Ian Somaiya, CFO, TCR2 Therapeutics and Iris Luo, MS, MBA Head of Business Development, North America, CStone Pharmaceuticals
Reply Retweet Like
CancerProgress by Cello Health BioConsulting retweeted
CancerProgress by Cello Health BioConsulting Apr 3
Late-breaking additions to our CP panels, making them all the more stellar! Martin Lehr, CEO, Context Therapeutics and Patrick Mahaffy, President & CEO, Clovis Oncology
Reply Retweet Like
CancerProgress by Cello Health BioConsulting retweeted
CancerProgress by Cello Health BioConsulting Apr 3
Late-breaking additions to our CP panels, making them all the more stellar! Jill O'Donnell-Tormey, PhD, Chief Executive Officer & Director, Scientific Affairs, Cancer Research Institute
Reply Retweet Like
CancerProgress by Cello Health BioConsulting retweeted
CancerProgress by Cello Health BioConsulting Apr 3
Late-breaking additions to our CP panels, making them all the more stellar! Vanessa Lucey, PhD, MBA, Director, Cancer Research Institute
Reply Retweet Like
CancerProgress by Cello Health BioConsulting retweeted
CancerProgress by Cello Health BioConsulting Apr 3
Late-breaking additions to our CP panels, making them all the more stellar! Apostolia-Maria Tsimberidou, MD, PhD, Professor, Department of Investigational Cancer Therapeutics M. D. Anderson Cancer Center, University of Texas
Reply Retweet Like
CancerProgress by Cello Health BioConsulting retweeted
CancerProgress by Cello Health BioConsulting Apr 3
Late-breaking additions to our CP panels, making them all the more stellar! Nicholas Sarlis, MD, PhD, FACP, FAPCR, Chief Medical Officer & Executive VP, Sellas Life Sciences Group, Inc.
Reply Retweet Like
CancerProgress by Cello Health BioConsulting retweeted
David Miller Apr 2
Nice mouse data from in Nectin-4+ tumors.
Reply Retweet Like
CancerProgress by Cello Health BioConsulting Apr 3
Late-breaking additions to our CP panels, making them all the more stellar! Ian Somaiya, CFO, TCR2 Therapeutics and Iris Luo, MS, MBA Head of Business Development, North America, CStone Pharmaceuticals
Reply Retweet Like
CancerProgress by Cello Health BioConsulting Apr 3
Late-breaking additions to our CP panels, making them all the more stellar! Martin Lehr, CEO, Context Therapeutics and Patrick Mahaffy, President & CEO, Clovis Oncology
Reply Retweet Like
CancerProgress by Cello Health BioConsulting Apr 3
Late-breaking additions to our CP panels, making them all the more stellar! Jill O'Donnell-Tormey, PhD, Chief Executive Officer & Director, Scientific Affairs, Cancer Research Institute
Reply Retweet Like
CancerProgress by Cello Health BioConsulting Apr 3
Late-breaking additions to our CP panels, making them all the more stellar! Vanessa Lucey, PhD, MBA, Director, Cancer Research Institute
Reply Retweet Like
CancerProgress by Cello Health BioConsulting Apr 3
Late-breaking additions to our CP panels, making them all the more stellar! Apostolia-Maria Tsimberidou, MD, PhD, Professor, Department of Investigational Cancer Therapeutics M. D. Anderson Cancer Center, University of Texas
Reply Retweet Like